Telomerase inhibition is an effective therapeutic strategy in<i>TERT</i>promoter-mutant glioblastoma models with low tumor volume

Abstract

Our results support the idea that telomerase inhibition would be most effective at treating glioblastomas with low tumor burden, for example in the adjuvant setting after surgical debulking and chemoradiation.